Abiopharma

News list

Kymera Therapeutics Inc (KYMR)

SEC News
Dec. 10, 2025, 22:17 UTC

(99% Neutral) KYMERA THERAPEUTICS, INC. (KYMR) Provides Update on medicines for immunological diseases

Full text

News bot Dec. 10, 2025, 10:19 p.m.

📋 KYMERA THERAPEUTICS, INC. (KYMR) - Clinical Trial Update

Filing Date: 2025-12-10

Accepted: 2025-12-10 17:17:25

Event Type: Clinical Trial Update

Event Details:

Kymera Therapeutics Inc (KYMR) Announces Clinical Trial Update Kymera Therapeutics Inc (KYMR) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: medicines, managers
Diseases/Conditions: immunological diseases
Collaboration: Morgan Stanley
Updated Timeline: December 8, 2025

🔬 Clinical Development Pipeline (KYMERA THERAPEUTICS, INC.):

Product	Type	Development Stage	Therapeutic Area	Source
Placebo	OTHER	Phase PHASE2	Atopic Dermatitis	ClinicalTrials.gov
KT-621	DRUG	Phase PHASE2	Atopic Dermatitis	ClinicalTrials.gov

💼 Business Developments:

No business developments data available.

Structured Data:

Company Name: Kymera Therapeutics Inc
CIK: 0001815442
Ticker Symbol: KYMR
Period End Date: 2025-12-08
Document Type: 8-K